In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Omeros Corp (NASDAQ: OMER), with a price target of $25. The company’s shares closed on Friday at $15.98.
McCarthy observed:
“Prior to hitting the pass thru speed bump in January (and it’s just a speed bump), Omidria revenue grew to $22M in 3Q17. We expect these numbers to return in 4Q and for Omidria to grow with several factors to watch between now and then – 1Q expectations, getting back to pass-thru in October, impact of the VA and the healthy balance sheet.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -0.1% and a 38.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Currently, the analyst consensus on Omeros Corp is Moderate Buy and the average price target is $34.40, representing an 115.3% upside.
In a report issued on May 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $34 price target.
See today’s analyst top recommended stocks >>
Based on Omeros Corp’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $16.55 million. In comparison, last year the company had a GAAP net loss of $15.09 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded by Gregory A.
Read More on OMER:
